25 Sep Odylia announced as Amgen Prize finalist for The Odylia Collective
Atlanta, GA, September 10, 2024 —
Innovators in Rare Disease Diagnosis and Care Compete for The Amgen Prize and $150,0000 in Prize Funding at the Concordia Annual Summit
Odylia announced as top 5 finalist for the Amgen Prize: Innovation for Patients with Rare Disease. Follow the link to read the original article.
This year’s finalists will pitch their solutions to a panel of distinguished judges on the Concordia stage on September 24 in New York City. The Amgen Prize recipient will be announced live at Concordia the following day. Finalists include:
The Odylia Collective—pitched by Ashley Winslow, CEO and CSO of Odylia Therapeutics
A centralized marketplace that ensures drug development resources are accessible to patient groups and the rare disease research community
Care Management for the HPS Network “Pop-Up” Clinics in Puerto Rico—pitched by Donna Appell, Executive Director of Hermansky-Pudlak Syndrome Network Inc.
A cohesive care management system to facilitate improved health outcomes for this under-resourced rare community.
Data Coordination Center for Individualized Treatments—pitched by Winston Yan, Founding President of The N=1 Collaborative (N1C)
Introduces open data sharing across individualized, N-of-1 therapeutic programs to improve safety and efficacy for today’s and tomorrow’s rare disease patients.
Factor H La Luz Caregivers Programme—pitched by Ignacio Muñoz-Sanjuan, President of Factor H
A practical, financial, and emotional support programme for the caregivers of people with Huntington’s Disease in Venezuela.
SARA-Q—pitched by Mincheol Song, Director of Research at Voice of Calling NPO
A tool for quantitative and extensive data collection in the assessment of patients with rare disease ataxia.
—
For media inquiries, please contact:
Odylia Media
info@odylia.org
About Odylia Therapeutics
Odylia is a nonprofit biotech focused on bringing life-altering and lifesaving treatments to those with rare diseases. We have expertise in both preclinical and clinical drug development for rare diseases. Our vision is to change how drugs are developed for rare diseases by focusing on the science and patient needs, rather than the commercial potential. We partner with patient communities, researchers, clinicians, industry, and financial donors to bring promising therapeutics to clinical trials. In addition to our gene therapy development pipeline, we partner with rare disease patient groups, early-stage gene therapy companies, and academic researchers to further their rare disease drug development efforts through our Brydge Solutions program. Patient groups, companies, and researchers interested in learning more about Odylia Therapeutics’ services contact us at info@odylia.org and follow us on LinkedIn (Odylia Therapeutics), Instagram (@OdyliaTx), and YouTube (@OdyliaTx), and Facebook (Odylia Therapeutics). For additional information, visit https://odylia.org.
About The Odylia Collective
Odylia is building a centralized marketplace to ensure critical resources are findable and accessible for patient groups and other members of the rare disease research community. Ultimately, centralizing these resources will decrease wasted time and money, and increase the speed at which drugs are developed for rare diseases. Driven by the complexity in connecting the disparate pieces of drug development, The Odylia Collective will connect patient groups and the research community with a growing collection of service providers including: manufacturers, clinical CROs, animal testing, cell line producers, biobanking services, and more.